BNTC Key Statistics, Chart & Performance
The current stock price of BNTC is 13.58 USD. In the past month the price increased by 13.17%. In the past year, price increased by 20.93%.
BNTC Latest News, Press Relases and Analysis
BNTC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About BNTC
Company Profile
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Company Info
BENITEC BIOPHARMA INC
3940 Trust Way
Hayward CALIFORNIA 94545 US
CEO: Jerel Banks
Employees: 16
Phone: 15107800819
BENITEC BIOPHARMA INC / BNTC FAQ
What does BENITEC BIOPHARMA INC do?
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
What is the current price of BNTC stock?
The current stock price of BNTC is 13.58 USD. The price increased by 3.03% in the last trading session.
Does BENITEC BIOPHARMA INC pay dividends?
BNTC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BNTC stock?
BNTC has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is BNTC stock listed?
BNTC stock is listed on the Nasdaq exchange.
What do analysts say about BENITEC BIOPHARMA INC (BNTC) stock?
14 analysts have analysed BNTC and the average price target is 26.52 USD. This implies a price increase of 95.29% is expected in the next year compared to the current price of 13.58.
What is the Price/Earnings (PE) ratio of BENITEC BIOPHARMA INC (BNTC)?
BENITEC BIOPHARMA INC (BNTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
BNTC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BNTC. When comparing the yearly performance of all stocks, BNTC is one of the better performing stocks in the market, outperforming 72.37% of all stocks.
BNTC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BNTC. While BNTC has a great health rating, there are worries on its profitability.
BNTC Financial Highlights
Over the last trailing twelve months BNTC reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 80.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.75% | ||
| ROE | -42.86% | ||
| Debt/Equity | 0 |
BNTC Forecast & Estimates
14 analysts have analysed BNTC and the average price target is 26.52 USD. This implies a price increase of 95.29% is expected in the next year compared to the current price of 13.58.